Bloch Stephen M sold $6.1M of LQDA (indirect holdings)

Bloch Stephen M sold 75,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $80.68 ($80.18–$81.31, $6.05M total) across 3 trades over 2026-07-06 to 2026-07-07.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jul 8, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this disclosure alone does not change the company’s operating outlook.

02

Market read

A director’s $6.05M open-market sale is disclosed, which may slightly affect sentiment but lacks fundamental new information.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no reason for the sale or any concurrent operational/company updates.

Relevance 6/10Novelty 3/10Timing: today’s SEC Form 4 filing (after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by a director via indirect holdings.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp director Stephen M Bloch sold 75,000 shares in open-market trades totaling about $6.05M, per Form 4 filed today.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing provides transaction size, dates, and price range, but no accompanying company-specific news (earnings, guidance, deals, or regulatory actions). Insider sales can be interpreted both ways, and the article lacks additional context.

Market effects

No clear sector read-through from a single director sale without additional company developments.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs and may not reflect a bearish view of Liquidia’s prospects.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Stephen M. Bloch

    Director who sold 75,000 shares across three open-market trades totaling about $6.05M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.